CN106573000A - 作为抗癌药物的芳基胺取代的喹喔啉 - Google Patents

作为抗癌药物的芳基胺取代的喹喔啉 Download PDF

Info

Publication number
CN106573000A
CN106573000A CN201580036998.3A CN201580036998A CN106573000A CN 106573000 A CN106573000 A CN 106573000A CN 201580036998 A CN201580036998 A CN 201580036998A CN 106573000 A CN106573000 A CN 106573000A
Authority
CN
China
Prior art keywords
cancer
pharmaceutical composition
pp2a
compound
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580036998.3A
Other languages
English (en)
Other versions
CN106573000B (zh
Inventor
陈昆锋
萧崇玮
陈志宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN106573000A publication Critical patent/CN106573000A/zh
Application granted granted Critical
Publication of CN106573000B publication Critical patent/CN106573000B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供式I(a)～(d)和式II化合物，所述化合物能抑制蛋白质磷酸酶2A癌性抑制因子(PP2A)，可作为蛋白质磷酸酶2A(PP2A)促进剂和癌蛋白SET拮抗剂，且能有效治疗癌症。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201580036998.3A 2014-07-07 2015-07-07 作为抗癌药物的芳基胺取代的喹喔啉 Active CN106573000B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462021214P 2014-07-07 2014-07-07
US62/021,214 2014-07-07
PCT/CN2015/083466 WO2016004856A1 (zh) 2014-07-07 2015-07-07 作为抗癌药物的芳基胺取代的喹喔啉

Publications (2)

Publication Number Publication Date
CN106573000A true CN106573000A (zh) 2017-04-19
CN106573000B CN106573000B (zh) 2020-02-07

Family

ID=55063580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580036998.3A Active CN106573000B (zh) 2014-07-07 2015-07-07 作为抗癌药物的芳基胺取代的喹喔啉

Country Status (7)

Country Link
US (1) US10189795B2 (zh)
EP (1) EP3167887B1 (zh)
JP (1) JP6462868B2 (zh)
KR (1) KR101957613B1 (zh)
CN (1) CN106573000B (zh)
TW (1) TWI660949B (zh)
WO (1) WO2016004856A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935944A (zh) * 2017-10-31 2018-04-20 广西师范大学 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2278244A1 (en) * 1997-01-21 1998-07-23 Nissan Chemical Industries, Ltd. Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
WO2002020463A2 (en) * 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
WO2006044402A1 (en) * 2004-10-14 2006-04-27 Compass Pharmaceuticals Llc Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE288610C (zh) *
WO2012045196A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2278244A1 (en) * 1997-01-21 1998-07-23 Nissan Chemical Industries, Ltd. Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
WO2002020463A2 (en) * 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
WO2006044402A1 (en) * 2004-10-14 2006-04-27 Compass Pharmaceuticals Llc Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
BAGINENI PRASAD等: "AlCl3 induced C–N bond formation followed by Pd/C–Cu mediated coupling–cyclization strategy: synthesis of pyrrolo[2,3-b]quinoxalines as anticancer agents", 《TETRAHEDRON LETTERS》 *
DIANAL OCKHAR等: "Aryloxy-derivatives of Pyrimidines, Quinoxalines, and Quinolines", 《JOURNAL OF THE CHEMICAL SOCIETY》 *
H-C YU等: "Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A", 《CELL DEATH AND DISEASE》 *
K. WAISSER等: "Antimycobacterial activity of some 2,3-dianilinoquinoxaline dericatives with substituens in position 6", 《SCI. PHARM.》 *
K. WASISSER等: "Antimycobacterial activity of some 2,3-dianilinoquinoxaline derivatives", 《PHARMAZIE》 *
P. VIJAYA BABU等: "Ligand/PTC-free intramolecular Heck reaction: synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo", 《ORG. BIOMOL. CHEM.》 *
S. D. CARTER等: "QUINOXALINES AND RELATED COMPOUNDS-X’ THE FORMATION OF INDOLO[2,3-b]QUINOXALINES AND 2-p-AMINOPHENYL-3-ANILINOQUINOXALINES FROM 2-ANILINOQUINOXALINES", 《TETRAHEDRON》 *
S.A. KHAN等: "SYNTHESIS AND ANTlMlCROBlAL ACTIVITY OF 2,3-Dl-SUBSTITUTED QUINOXALINES", 《INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY》 *
WONSEOK CHO等: ""Synthesis of New Bis(amidine)−Cobalt Catalysts and Their Application to Styrene Polymerization", 《ORGANOMETALLICS》 *
无: "《STN-REGISTRY RN 1015590-66-5》", 18 April 2008 *
无: "《STN-REGISTRY RN 297763-23-6》", 20 October 2000 *
无: "《STN-REGISTRY RN 304883-93-0》", 29 November 2000 *
无: "《STN-REGISTRY RN 331848-77-2》", 19 April 2001 *
无: "《STN-REGISTRY RN 354989-33-6》", 6 September 2001 *
无: "《STN-REGISTRY RN 358371-27-4》", 24 September 2001 *
无: "《STN-REGISTRY RN 392710-13-3》", 15 February 2002 *
无: "《STN-REGISTRY RN 451524-00-8》", 16 September 2002 *
无: "《STN-REGISTRY RN 799787-14-7》", 20 December 2004 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107935944A (zh) * 2017-10-31 2018-04-20 广西师范大学 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法
CN107935944B (zh) * 2017-10-31 2021-12-21 广西师范大学 具有抗肿瘤活性双芳基脲喹喔啉衍生物及其合成方法

Also Published As

Publication number Publication date
JP2017520626A (ja) 2017-07-27
CN106573000B (zh) 2020-02-07
TW201602086A (zh) 2016-01-16
EP3167887A1 (en) 2017-05-17
EP3167887A4 (en) 2017-11-22
KR20170024107A (ko) 2017-03-06
JP6462868B2 (ja) 2019-01-30
EP3167887B1 (en) 2021-03-24
KR101957613B1 (ko) 2019-03-12
US10189795B2 (en) 2019-01-29
WO2016004856A1 (zh) 2016-01-14
TWI660949B (zh) 2019-06-01
US20170204071A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
Lin et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor
JP6193268B2 (ja) Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
RU2497809C2 (ru) Производные нафталинкарбоксамида в качестве ингибиторов протеинкиназы и гистондеацетилазы, способы их получения и применение
Hong et al. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2
Li et al. 2, 4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K
CN106573000B (zh) 作为抗癌药物的芳基胺取代的喹喔啉
Wang et al. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC
CN108309982B (zh) 3位取代的5H-[1,2,4]三嗪[5,6-b]吲哚衍生物的用途
Zhao et al. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil
EP2596366A1 (en) Combination therapy with mdm2 and efgr inhibitors
Zhang et al. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer
RU2585528C2 (ru) Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
Song et al. Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer
US20230159498A1 (en) Small molecules for the treatment of autoimmune diseases and cancer
Jing et al. FNC inhibits non-small cell lung cancer by activating the mitochondrial apoptosis pathway
US20060034832A1 (en) Cell death inhibitor
Hu et al. Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma
US20220202785A1 (en) Small molecule inhibitors of gpcr gpr68 and related receptors for treating cancer, glioblastoma, and other indications
US9090617B1 (en) Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
Bai et al. NOD1 activation promotes cell apoptosis in papillary thyroid cancer
Liang et al. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers
US20200016100A1 (en) Method for ameliorating fibrosis using 1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)phenyl]urea
Li et al. Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme
Gao et al. Suppression of C6 gliomas via application of rat hyperplasia gene
JP2024509887A (ja) Ｅｐ３００分解剤および神経芽細胞腫におけるその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant